Theratechnologies (THTX) Shows Fast-paced Momentum But Is Still a Bargain StockZacks Investment Research • 02/26/24
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 GuidanceGlobeNewsWire • 02/21/24
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of ActionGlobeNewsWire • 02/20/24
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerGlobeNewsWire • 02/15/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Theratechnologies Inc. - THTXPRNewsWire • 02/07/24
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business UpdateGlobeNewsWire • 02/06/24
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLAGlobeNewsWire • 01/24/24
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License ApplicationGlobeNewsWire • 01/23/24
Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDAGlobeNewsWire • 01/02/24
Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration StatementPRNewsWire • 12/21/23
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading DoseGlobeNewsWire • 12/13/23
Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private PlacementGlobeNewsWire • 10/31/23
Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private PlacementGlobeNewsWire • 10/26/23
Theratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private PlacementGlobeNewsWire • 10/25/23
Theratechnologies' Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIVGlobeNewsWire • 10/19/23
Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with MarathonGlobeNewsWire • 10/16/23
Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)GlobeNewsWire • 10/13/23
Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration StudyGlobeNewsWire • 10/13/23
Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerGlobeNewsWire • 10/12/23
Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLAGlobeNewsWire • 10/04/23
Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business UpdatesGlobeNewsWire • 09/26/23